Personas / Equipo Humano

Susana Rives Solà

Buscador de publicaciones

Publicaciones

  • Bartoló-Ibars A, Aran A, Johansson AM, Ortiz-Maldonado V, Klein-González N, Alonso-Saladrigues A, James E, Urbano-Ispizua A, Rives-Solà S, Delgado J, González-Navarro EA, Kwok WW and Juan-Otero M.

    T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.

    Journal for ImmunoTherapy of Cancer . 13(9): .

    [doi:10.1136/jitc-2024-010792]

  • Awasthi R, Grupp SA, Waldron E, Yanik GA, Tam CS, Rives-Solà S, McGuirk JP, Pulsipher MA, Jaeger U, Myers GD, Borchmann P, Schuster SJ, Stefanski HE, Bishop MR, Chakraborty A, Masood A, Baruchel A and Waller EK.

    Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

    blood advances . 9(17): 4405-4414.

    [doi:10.1182/bloodadvances.2024014995]

  • Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E PhD, Wang HW, Kovach AE, Yuan CM, Delgado Colon D, Vasseur L, Bataller A, John S, Utley Lyons K, Friedes BD, Alonso-Saladrigues A, Abdel-Azim H, Balducci E, Aljudi A, Balsat M, Biery DN, Chamdin A, Chang BH, Cuevo RS MD, De Moerloose B, Dickens DS, Duffner UA, Duployez N, El Chaer F, Elliott MA, Escherich G, Fernandes S, Fitzjohn MR, Gahvari ZJ, Grupp SA, He RR MD, Harrison C, Hergott CB, Hsieh EM, Kim AS, Kuo DJ, Larson DP, Lee BJ, Leguay TT, Lindsley RC, Mangaonkar AA, Mezger K, Pacenta HL, Pan J, Provost MRM, Puri L, Raikar SS, Martinez AJ, Bristol IQ, Murphy KD, Reiman L, Redell MS, Reed K, Roth Guepin G, Rubinstein JD, Savasan S, Schafernak KT, McLean Stevens A, Talleur AC, Torres Carapia N, Vargaftig J, Vatsayan A, Wölfl M, Zhao L, Rives-Solà S, Fabrizio VA, Sasaki K, Aldoss I, Boissel N, Rheingold SR, Davis KL, Ghorashian S, Jacoby E, Popov A, Lamble AJ and Shah NN.

    Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

    Blood . 146(4): 437-455. Nº de citas: 3

    [doi:10.1182/blood.2024026655]

  • Vicente-Garces C, Fernandez-Isern G, Esperanza-Cebollada E, Richarte M, Crespo-Carrasco A, Montesdeoca S, Isola I, Sarrate E, Cuatrecasas E, Rives-Solà S, Dapena JL, Camós-Guijosa M and Vega-García N.

    RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia

    BRITISH JOURNAL OF HAEMATOLOGY . 206(5): 1355-1365.

    [doi:10.1111/bjh.20056]

  • Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives-Solà S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Mirones Aguilar I, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana Á, Barba P, Balsalobre P and Pérez-Martínez A.

    Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults

    EXPERIMENTAL HEMATOLOGY & ONCOLOGY . 14(1): 49-49. Nº de citas: 3

    [doi:10.1186/s40164-025-00638-3]

  • Pearson ADJ, Rossig C, Mackall CL, Shah NN, Baruchel A, Daems S, Anderson J, Biondi A, Bird N, Bodmer N, Brivio E, Buechner J, Calkoen FG, Cooper T, de Rojas T, Fox E, Gardner R, Ghorashian S, Heenen D, Ifversen M, Jacoby E, Juan-Otero M, Knox L, Komanduri K, Larghero J, Locatelli F, Ludwinski D, Majzner RG, McDonough J, Minard-Colin V, Nysom K, Pappo A, Park JR, Qasim W, Quintarelli C, Rives-Solà S, Rouce RH, Scobie N, Seitz C, Tasian SK, Weigel B, Weiner S, Zwaan CM and Vassal G.

    New models for the development of and access to CART-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis

    LANCET ONCOLOGY . 26(4): 214-224. Nº de citas: 1

    [doi:10.1016/S1470-2045(24)00736-8]

  • Marina Caballero Bellón, Bobillo-Perez S, Català-Temprano A, Alonso-Saladrigues A, Valls-Lafon A, Rives-Solà S and Jordán-García I.

    Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults

    Biomarkers . 30(2): 115-122. Nº de citas: 1

    [doi:10.1080/1354750X.2025.2454471]

  • Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives-Solà S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C and Menendez P.

    Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

    CELL REPORTS MEDICINE . 5(11): 101803-101803. Nº de citas: 1

    [doi:10.1016/j.xcrm.2024.101803]

  • Theron A, Alonso-Saladrigues A, Dapena JL, López-Duarte M, Diaz de Heredia C, Verdú-Amorós J, Sarrate E, Esperanza-Cebollada E, Cuatrecasas E, Andreu S, Conde N, Sanchez-Sierra N, Isola I, Camós-Guijosa M, Torrebadell-Burriel M, Rives-Solà S and Català-Temprano A.

    Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children

    BRITISH JOURNAL OF HAEMATOLOGY . : 186-194.

    [doi:10.1111/bjh.19862]

  • Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Rives-Solà S, Suleman W and Berrueco R.

    Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia

    THROMBOSIS AND HAEMOSTASIS . 124(10): 973-985.

    [doi:10.1055/a-2316-4547]